Masroni, Muhammad Sufyan Bin
Lee, Kee Wah
Lee, Victor Kwan Min
Ng, Siok Bian
Law, Chao Teng
Poon, Kok Siong
Lee, Bernett Teck-Kwong
Liu, Zhehao
Tan, Yuen Peng
Chng, Wee Ling
Tucker, Steven
Ngo, Lynette Su-Mien
Yip, George Wai Cheong
Nga, Min En
Hue, Susan Swee Shan
Putti, Thomas Choudary
Bay, Boon Huat
Lin, Qingsong
Zhou, Lihan
Hartman, Mikael
Loh, Tze Ping
Lakshmanan, Manikandan
Lee, Sook Yee
Tergaonkar, Vinay
Chua, Huiwen
Lee, Adeline Voon Hui
Yeo, Eric Yew Meng
Li, Mo-Huang
Chang, Chan Fong
Kee, Zizheng
Tan, Karen Mei-Ling
Tan, Soo Yong
Koay, Evelyn Siew-Chuan
Archetti, Marco
Leong, Sai Mun
Funding for this research was provided by:
National University of Singapore (NUS Postgraduate Research Scholarships, NUS Postgraduate Research Scholarships, Department of Pathology Startup Grants, Department of Pathology Startup Grants)
Ministry of Education - Singapore (T1- NUHS Joint Grant Call FY17 - 2nd call-10)
National Medical Research Council (NMRC–NIG NMRC/CNIG/1119/2014)
Singapore Cancer Society
Agency for Science, Technology and Research (A*STAR-SERC Public Service Fund 1121202021)
National University Health System (NUHS Bridging fund)
Article History
Received: 5 June 2023
Accepted: 5 November 2023
First Online: 14 December 2023
Declarations
:
: FFPE patient samples from chemotherapy-treated and treatment-naïve patients were obtained from the Department of Pathology, NUS, with prior approval obtained from NUS IRB.Protocols for <i>in vivo</i> experiments were approved by Institutional Animal Care and Use Committee (IACUC) at the National University of Singapore (protocol number 009/12 & R16-0019)
: Lihan Zhou and Mo-Huang Li are employed as Chief Executive Officers of MiRXES Pte Ltd and CellSievo Pte Ltd respectively.